This is a single-center, open-label, Phase I clinical study of TCR-T cells for the treatment of the recurrent/metastatic solid tumors patients who had failed standard therapy.~Objective:~To evaluate the safety and efficacy of TCR-T cells for the treatment of advanced solid tumors.~Eligibility:~Adults aging 18-70 with advanced solid tumors~Design:~Patients will undergo screening tests, including imaging procedures, heart and lung tests, and lab tests.~Patients will have leukapheresis. Blood will be removed through a needle in the arm. A machine separates the white blood cells. The rest of the blood is returned through a needle in the other arm.~Engineered T cells will be re-infused into the patient. Patients will stay in hospital and be evaluated
New York Esophageal Squamous Cell Carcinoma 1 (NY-ESO-1) is a cancer-testis antigen (CTA) which is expressed in various tumors. In TCR-T therapy, researchers take the blood of a certain patient, select T cells and insert genes into the cell that expressing a kind of protein that targeting NY-ESO-1. The genetically engineered cells are called NY-ESO-1 TCR-T cells. Then the engineered cells are re-infused to the cancer patients to cure the disease or prolong life.